| scholarly article | Q13442814 |
| P2093 | author name string | Itamar Shalit | |
| Zmira Samra | |||
| Nir Osherov | |||
| Yona Shadkchan | |||
| P2860 | cites work | In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates | Q28345261 |
| Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase | Q33754208 | ||
| Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia | Q34104748 | ||
| Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections | Q34481664 | ||
| Invasive Aspergillus infections in hematologic malignancy patients | Q34692206 | ||
| Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro | Q35132244 | ||
| In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. | Q39651019 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens | Q39819768 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1416-1418 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points | |
| P478 | volume | 47 |
| Q36895839 | A comparative evaluation of properties and clinical efficacy of the echinocandins |
| Q37263780 | Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions |
| Q36201569 | Antifungal combination therapy: clinical potential |
| Q33719294 | Aspergillus infections in transplant recipients |
| Q41835779 | Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata |
| Q35537846 | Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis |
| Q40463769 | Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. |
| Q35947161 | Coding tandem repeats generate diversity in Aspergillus fumigatus genes |
| Q76381447 | Combination antifungal therapy |
| Q36895652 | Combination antifungal therapy: the new frontier |
| Q37705303 | Combinatorial strategies for combating invasive fungal infections. |
| Q33857685 | Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus |
| Q44619968 | Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus |
| Q46290055 | Comparison Between Etest and Broth Microdilution Methods for Testing Itraconazole-Resistant Aspergillus fumigatus Susceptibility to Antifungal Combinations |
| Q39458862 | Echinocandins in antifungal pharmacotherapy. |
| Q36295480 | Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q40164956 | Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae |
| Q41973262 | In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. |
| Q41815954 | In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans |
| Q39913400 | In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. |
| Q39954754 | In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. |
| Q42689671 | In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies |
| Q36492208 | In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus |
| Q36558484 | In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. |
| Q35561985 | New approaches to invasive fungal infections |
| Q34956645 | New methods to assess susceptibilities of Aspergillus isolates to caspofungin |
| Q33981062 | Newer systemic antifungal agents : pharmacokinetics, safety and efficacy |
| Q90162266 | Posaconazole Alone and in Combination with Caspofungin for Treatment of Experimental Exserohilum rostratum Meningoencephalitis: Developing New Strategies for Treatment of Phaeohyphomycosis of the Central Nervous System |
| Q35587115 | Status of combination therapy for refractory mycoses |
| Q81533852 | [In vitro activity of the echinocandins. How should it be evaluated?] |
| Q45942581 | [Potential of anidulafungin in combined therapy]. |
Search more.